ACT Accelerator (ACT-A) and COVAX

Vx safety ecosystem workshop

9 September 2020
RECAP:
ACT-A’s goal is to reduce COVID mortality & severe disease through accelerated development, equitable allocation & scaled up delivery of...

Vaccines
2 billion doses by the end of 2021

Therapeutics
245 million courses by mid-2021

Diagnostics
500 million tests by mid-2021

...thereby protecting health systems & restoring societies & economies
• **3 vertical Pillars are the primary drivers** of ACT’s product work

• A cross-cutting **Access & Allocation Workstream** delivers equity

• **A Health Systems Connector** drives optimal utilization

• **Support mechanisms** incl. 2 Special Envoys & ACT Support Hub
RECAP: The ACT Timeline

Phase 1:
- Expand existing diagnostics & identify viable new tools

Phase 2:
- Introduce new tools to supplement current approach

Phase 3:
- Transition to new tools as primary intervention

2020
- Q2
- Q3
- Q4

2021
- Q1
- Q2
- Q3
- Q4

- Initiate production on promising new products
- Simultaneous rollout in priority populations
- Full scale production and delivery for mass coverage

Work across the 4 Pillars will be adapted to the evolving epidemiology, trial results, and tools
The case for ACT is even stronger
Vaccines, therapeutics & diagnostics are essential to global recovery

Lockdowns are not a solution
• Unsustainable in HICs / UMICs & unimplementable in LMICs

All populations are still at risk
• Serology data reveal massive immunity gaps everywhere

Countries can’t beat COVID alone
• Interconnectivity undermines every country’s emergence from lockdown

COVID is not coming under control

1. Based on University of Oxford's Coronavirus Government Response Tracker, “Stringency” measures the strictness of ‘lockdown style’ NPI policies that primarily restrict behavior

SOURCE: Oxford COVID-19 Government Response Tracker; WHO
ACT is successfully harnessing the international health ecosystem

Key success factors: deep engagement of Principals, integrated workplans & budgets, leveraging the best of each agency
## ACT already has an impressive track record

### Vaccines
- 9 vaccine candidates already in portfolio
- **Broadest portfolio** across geographies & tech platforms
- **COVAX Vaccines Facility** launched (>170 countries, 70% global pop)

### Therapeutics
- **1st new treatment secured** for LMICs (Dexamethasone)
- Key novel drugs under evaluation

### Diagnostics
- 50+ test kits under evaluation
- 10+ million kits procured (with Dx consortium)
- Promising **rapid Antigen diagnostic** test(s) identified

### Allocation
- Equitable Access Principles agreed
- **Draft Allocation Framework** issued for consultation
Overview of COVAX setup – agreed organization

3 workstreams

1. Not representing the structure but the organization of working teams/sub-teams within COVAX
Three components informing countries to formulate the in-country vaccination strategy

**Countries**

- **SAGE**
  *Provides guidance and policy advice on specific candidates, e.g. on vaccination strategies*

- **Allocation Framework**
  *Sets frame for overarching public health goals and priorities (candidate independent)*

- **Regulatory, Safety & Monitoring**
  *Provides guidance on regulatory issues, safety and monitoring*
BACK-UP
Challenges heading into the next phase of ACT-A

At 24 August

**Insufficient financing**
US$ B rounded (Vaccines, Tx, Diagnostics only)

- **Vx (Vaccines):** $31 B
  - **First pledging:** $3.4 B
  - **Second pledging:** $0.4 B
  - **Financing gap:** $28 B
- **Tx (Tests):** $18
- **Dx (Diagnoses):** $7

**Inefficient vaccine distribution**
Vaccine doses secured\(^1\), M doses by 2021

- **Domestic\(^2\):** 1,000+
- **Regional\(^3\):** 1,700
- **Global (COVAX):** 2,000

---

1. Based on publicly disclosed agreements
2. Cumulative numbers
3. European Commission Inclusive Vaccines Alliance

SOURCE: IMF Estimates; Press releases; OECD; WHO; World Bank; The Economist Intelligence Unit